久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

US EUROPE AFRICA ASIA 中文
Business / latest news

Sinobioway taps into US biotechnology industry

By LIA ZHU in San Francisco (chinadaily.com.cn) Updated: 2016-06-10 14:26

Sionbioway Group Co, Ltd, a major biotech company in China, has been seeking partnerships with US biotech companies through technology and capital investments to help realize its goal of starting a revolution in the bioindustry.

Sinobioway and BioAtla LLC, a San Diego-based company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, are working collaboratively to develop several CAB candidates for the Chinese market.

In May 2015, the two companies entered into a strategic collaboration for the development and commercialization of select CAB antibodies and other CAB-based therapeutics in China.

Under the agreement, the companies selected their first product programs for development in January this year. BioAtla also received $19 million in program payments and equity investment from Sinobioway as part of a total of more than $70 million in payments and investment from Sinobioway over the next 12 months.

As part of the agreement, Sinobioway has exclusive rights to develop and commercialize selected CAB antibodies in China.

"Collaboration with overseas companies means more than just marketing products. Sinobioway aims to find the best technologies and best partners through direct investment," said Alex Zhang, investment and financing director of Sinobioway.

"Some innovative companies in the US have very limited resources in capital, manufacturing and marketing. A partnership with Chinese companies like Sinobioway means they have access to China's huge market and production capacity," he said, adding that an office would open in June in San Diego to facilitate investment and potential partnerships.

The strategic collaboration between Sinobioway and BioAtla is considered the keystone of both companies' long-term plans to address the growing high demand for innovative therapeutic products in the China pharmaceutical market.

"China is an immensely important opportunity for CABs and we are excited to be working with Sinobioway with its demonstrated commitment and strong capabilities to execute and to fulfill our mutual goals," said Jay Short, president and CEO of BioAtla, in a statement.

Sinobioway has also collaborated with Baylor College of Medicine to introduce the chimeric antigen receptor (CAR) T-cell therapy technology, a breakthrough to tumor treatment, to China.

At a cost of about $30.5 million, Sinobioway has built a Good Manufacturing Practice (GMP) facility for cell preparation and a molecular biology lab for product testing.

By collaborating with leading local hospitals in China, the company said "great results" have been achieved in treating acute lymphoblastic leukemia, Burkitt lymphoma, pancreatic cancer and neuroblastoma.

Founded in 1992,Sinobiowayis affiliated with Peking University and headquartered in the 20-heactare Peking University Biocity, which houses the company's administration and R&D operations.

Encompassing more than 50 subsidiaries, Sinobioway's businesses span biomedicine, bioagriculture, bioenergy, bioenvironment, bioservice, biomanufacturing and biointelligence.

More than a dozen manufacturing bases have been built across China and five major ones are being constructed, with each of them is, or will be, the world's largest of its kind, said the company.

Among them, the Bantang Bioeconomy Experimental Zone in Hefei, Anhui province, is expected to have 100 production lines on completion and will meet the GMP requirements of China, the US, the World Health Organization and the European Union, according to the company.

Placing a premium on the R&D of new drugs and the advancement of its biomedical technology, Sinobioway is constructing a highly efficient R&D system, or what Pan Aihua, chairman of Sinobioway, called "new drug expressway", to address health issues.

Expected to be completed by 2025, the system aims to cut the average R&D cost to less than $50 million and shorten the pharmaceutical development cycle to eight years from the current 10 to 15 years, obtaining approval for about 25 new drugs annually.

"I believe in the coming decade or two, we human beings will enter the era of bioeconomy," said Pan. "Sinoboiway aims to become a flagship of the bioeconomy and will lead the next wave of industrial revolution."

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 亚洲乱码一二三四五六区 | free性欧美hd另类精品 | 污美女网站www在线观看 | 手机在线免费看毛片 | 欧美精品黄页免费高清在线 | 色悠久久久久综合网伊人男男 | 国产精品jvid在线观看 | 真人毛片免费全部播放完整 | 精品欧美成人高清视频在线观看 | 欧美黑人xxxxxxxxxx | 2019在线亚洲成年视频网站 | 女性无套免费网站在线看 | 亚洲欧美日韩在线线精品 | 亚洲视频国产 | 久久综合狠狠综合狠狠 | 久久免费视频6 | 欧美满嘴射 | 亚洲第一网色综合久久 | 国产精品亲子乱子伦xxxx裸 | 中文字幕日韩精品有码视频 | 久久久久国产精品免费网站 | 91精品国产9l久久久久 | 99精品在线| 美女一级毛片免费看看 | 亚洲第一网站 | 亚洲国产成人综合精品2020 | 99re9精品视频在线 | 国产成人亚洲毛片 | 老司机深夜影院入口aaaa | 免费在线观看一级毛片 | 日韩免费高清一级毛片 | 美女被免费视频的网站 | 毛片直接看 | 国产一区国产二区国产三区 | 中文字幕 日韩在线 | 亚洲精品天堂一区在线观看 | 欧美日本一道道一区二区三 | 欧美久久久久久 | 欧美成人特黄级毛片 | 精品国产乱码久久久久久一区二区 | 毛片的网址|